Clinical Lymphoma Myeloma and Leukemia This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

SOHO State of the Art Updates and Next Questions | A Modern Approach to the Systemic Treatment of Advanced CTCL
The term cutaneous T-cell lymphoma (CTCL) is a general term for T-cell lymphomas that are found primarily in skin. The most common CTCL entities, mycosis fungoides (MF) and Sezary syndrome (SS) are incurable diseases with a plethora of conventional treatment options. In the past treatment options have been selected primarily according to stage. Given newer targeted therapies with varied response in different body compartments, we suggest a compartment-guided algorithm that may enhance response rates directing the selection of the most efficacious treatment options. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 16, 2023 Category: Hematology Authors: Danielle Brazel, Lauren Pinter-Brown Source Type: research

Association of KIR genes polymorphism and its HLA ligands in Diffuse Large B-cell Lymphoma
The objective of the present work was to determine the polymorphism of KIR genes in Brazilian patients with DLBCL. Furthermore, we evaluated the association between the polymorphism of these genes and their ligands with the clinical course of the disease. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 9, 2023 Category: Hematology Authors: Marangon Amanda, Cardozo Daniela, Guimar ães Fernando, Marques Silvia, Lieber Sofia, Delamain Márcia, Aranha Francisco, Visentainer Jeane, de Souza Cármino Tags: Original Study Source Type: research

Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma
This study evaluated SARS-CoV-2 spike-binding IgG antibody levels following COVID-19 vaccination among non-Hodgkin lymphoma and multiple myeloma CAR T therapy recipients. In this retrospective study, we evaluated 104 patients that received CAR T therapy; of those 17 patients were evaluated for antibody spike titers following CAR T therapy. We found that only a minority of non-Hodgkin lymphoma and multiple myeloma patients were able to mount a clinically relevant (>250 IU/mL) antibody response. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 7, 2023 Category: Hematology Authors: Julia E. Wiedmeier-Nutor, Madiha Iqbal, Allison C. Rosenthal, Evandro D. Bezerra, Juan Esteban Garcia-Robledo, Radhika Bansal, Patrick B. Johnston, Matthew Hathcock, Jeremy T. Larsen, P. Leif Bergsagel, Yucai Wang, Craig B. Reeder, Jose F. Leis, Rafael Fo Tags: Original Study Source Type: research

Response to COVID-19 vaccination post CAR T therapy in patients with non-Hodgkin lymphoma and multiple myeloma
COVID-19 adversely affects individuals with cancer. Several studies have found that seroconversion rates among patients with hematologic malignancies are suboptimal when compared to patients without cancer. Patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) are immunocompromised due to impaired humoral and cellular immunity in addition to prescribed immunosuppressive therapy. Chimeric antigen receptor T-cell (CAR T) therapy is now widely used for NHL and MM, but little is known about seroconversion rates after COVID-19 vaccination among these populations. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 7, 2023 Category: Hematology Authors: Julia E. Wiedmeier-Nutor, Madiha Iqbal, Allison C. Rosenthal, Evandro D. Bezerra, Juan Esteban Garcia-Robledo, Radhika Bansal, Patrick B. Johnston, Matthew Hathcock, Jeremy T. Larsen, P. Leif Bergsagel, Yucai Wang, Craig B. Reeder, Jose F. Leis, Rafael Fo Tags: Original Study Source Type: research

Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: the phase 3 OCTANS study
Daratumumab is a human IgG κ monoclonal antibody targeting CD38 with a direct on-tumor1-4 and immunomodulatory5-7 mechanism of action. Based on the positive results of numerous clinical trials,8-15 intravenous daratumumab 16 mg/kg is approved in many countries as monotherapy for patients with relapsed or refractory multiple myeloma (MM) or in combination with standard-of-care regimens for patients with relapsed or refractory MM or newly diagnosed MM (NDMM).16, 17 (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 3, 2023 Category: Hematology Authors: Weijun Fu, Soo-Mee Bang, Honghui Huang, Kihyun Kim, Wei Li, Gang An, Je-Jung Lee, Zhen Cai, Jie Jin, Yafei Wang, Tung-Liang Lin, Chor Sang Chim, Ming Qi, Jianping Wang, Xiaolin Lu, Yang Song, Bin Jia, Xue Yang, Wenyu Liu, Tianyuan Zhou, Lu Yin, Yunan Li, Tags: Original Study Source Type: research

Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
The efficacy and safety of teclistamab in patients with RRMM who received ≥3 prior lines of therapy and were triple-class exposed (TCE) are being evaluated in the single-arm, multicohort, phase I/II MajesTEC-1 trial (NCT04557098). We evaluated the comparative effectiveness of teclistamab vs physician's choice (PC) of therapy in TCE RRMM patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 2, 2023 Category: Hematology Authors: Mar ía-Victoria Mateos, Ajai Chari, Saad Z. Usmani, Hartmut Goldschmidt, Katja Weisel, Keqin Qi, Anil Londhe, Sandhya Nair, Xiwu Lin, Lixia Pei, Eric Ammann, Rachel Kobos, Jennifer Smit, Trilok Parekh, Alexander Marshall, Mary Slavcev, Philippe Moreau Tags: Original Study Source Type: research

Patient Confidence and Information Preferences during the Treatment Decision-making Process: Results from a Large Multiple Myeloma Patient Survey Across 12 Countries in Europe and Israel
The relapsing nature of multiple myeloma (MM) means that patients typically receive different and multiple lines of therapy, requiring many treatment decisions over the disease course. The aim of this study was to explore patient confidence and information preferences during the treatment decision-making process. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 1, 2023 Category: Hematology Authors: Ulf-Henrik Mellqvist, H. Tilman Steinmetz, Aurore Perrot, Erik Aerts, Paul Williams, Ana Vallejo, Kate Morgan, Ananda Plate, Ana Mar ía Rodríguez-Leboeuf, Renaud Desgraz, Eva Hellqvist Franck, Lucy De Costa, Alessandra Brescianini, Heinz Ludwig Tags: Original Study Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 25, 2023 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 25, 2023 Category: Hematology Source Type: research

SOHO State of the Art Updates and Next Questions | Update on Treatment-Free Remission in Chronic Myeloid Leukemia (CML)
Tyrosine kinase inhibitor (TKI) discontinuation, also known as treatment-free remission (TFR) is currently one of the main goals of chronic myeloid leukemia (CML) therapy. TKI discontinuation should be considered in eligible patients for several reasons. Specifically, TKI therapy is associated with reduced quality of life, long-term side effects and a heavy financial burden on both the patients and society. TKI discontinuation is a particularly important goal for younger patients diagnosed with CML because of the treatment's effects on their growth and development in addition to potential long-term side-effects. (Source: C...
Source: Clinical Lymphoma, Myeloma and Leukemia - February 24, 2023 Category: Hematology Authors: Sherrie Mikhaeel, Ehab Atallah Source Type: research

Monoclonal Gammopathy of Undetermined Significance: A Comprehensive Review
Monoclonal gammopathy refers to the presence of abnormal protein in the blood, originating from plasma cells in the bone marrow1. These abnormal circulating monoclonal proteins can range from the highly prevalent asymptomatic condition, monoclonal gammopathy of undetermined significance (MGUS), to less common and more advanced disorders like multiple myeloma (MM)1,2. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 21, 2023 Category: Hematology Authors: Jasneet Kaur, Sai Sudha Valisekka, Maha Hameed, Pushyami Satya Bandi, Samyuktha Varma, Chibuzor Joseph Onwughalu, Hany Ibrahim, Himani Mongia Tags: Review Article Source Type: research

A novel hypothesis: Certain KIR/cognate ligand containing genotypes differ in frequency among patients with myeloma and have an effect on age of disease onset
Natural Killer (NK) cells are known to have cytotoxic effects mediated through Killer Immunoglobulin-Like Receptors (KIRs) and their cognate ligands. Role of KIRs in myeloma is yet unresolved. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 20, 2023 Category: Hematology Authors: Meral Beksac, Hasan Yalim Akin, Guldane Cengiz Seval, Pinar Yurdakul Mesutoglu, R ıdvan Goksel Anliacik, Ezgi Anliacik, Gunhan Gurman, Ergun Karaagaoglu, Klara Dalva Tags: Original Study Source Type: research

Association of Minimal Residual Disease Negativity Rates with Progression Free Survival in Frontline Therapy Trials for Newly Diagnosed Multiple Myeloma: A Meta-analysis
Current frontline therapies for newly diagnosed multiple myeloma patients have significantly prolonged progression-free survival (PFS). This has led to interest in minimal residual disease negativity (MRDng) as an efficacy-response biomarker and possible surrogate endpoint. A meta-analysis was conducted to explore the surrogacy of MRD for PFS and quantify the relationship between MRDng rates and PFS at the trial level. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 20, 2023 Category: Hematology Authors: Joseph Ficek, Shuai Sammy Yuan, Eleftheria Kalaitzaki, Alessandra Tosolini, Ling Du, Brandon E Kremer, Katherine Davy, Helen Zhou, Tai-Tsang Chen Tags: Review Article Source Type: research

A phase I trial of allogeneic γδ T lymphocytes from haploidentical donors in patients with refractory or relapsed acute myeloid leukemia.
We report the results of a phase I clinical trial NCT03790072 of an adoptive transfer of γδ T lymphocytes from haploidentical donors in patients with refractory/relapsed acute myeloid leukaemia after lymphodepletion regimen. Healthy donor mononuclear cells collected by leukapheresis were consistently expanded to generate products of 109 to 1010 γδ T cells. Seven patients received do nor-derived T cell product at doses of 106/kg (n=3), 107/kg (n=3), and 108/kg (n=1). Four patients had bone marrow evaluation at Day 28. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 10, 2023 Category: Hematology Authors: Jan Vydra, Emilio Cosimo, Petr Lesn ý, Richard Sebastian Wanless, John Anderson, Alan George Clark, Angela Scott, Emma Kate Nicholson, Michael Leek Tags: Original Study Source Type: research

Early Real-World First-Line Treatment with Venetoclax Plus HMAs Versus HMA Monotherapy Among Patients with AML in a Predominately US Community Setting
Acute myeloid leukemia (AML) is an aggressive, life-threatening hematologic malignancy with a complex pathophysiology, in which the bone marrow produces abnormal myeloblasts, red blood cells, or platelets. AML predominantly affects older adults.1, 2 Due to advanced age and/or coexisting comorbidities (e.g., a history of congestive heart failure), and despite prevalence of unfavorable cytogenetic markers, many patients with AML are not fit for intensive induction chemotherapy.3 Treatment with hypomethylating agents (HMAs) such as azacitidine (Aza) or decitabine (Dec) was considered the standard of care for these patients, w...
Source: Clinical Lymphoma, Myeloma and Leukemia - February 10, 2023 Category: Hematology Authors: Anda Gershon, Esprit Ma, Tao Xu, Melissa Montez, Kiran Naqvi, Grace Ku, Wendy Wei-Han Cheng, Evelyn M. Flahavan, Vamsi Kota, Daniel R. Greenwald Tags: Original Study Source Type: research